RESUMEN
OBJECTIVE: The purpose of this study was to track changes in selected subpopulations of lymphocytes in the blood of dogs infected with Babesia (B.) canis and treated with imidocarb. MATERIAL AND METHODS: The study included 16 dogs divided into two groups. The first group (n = 6) consisted of healthy control animals. Dogs of the se- cond group (n = 10) were infected with B. canis and after establishment of the diagnosis each animal received a single dose of imido- carb (5 mg/kg). Flow cytometry was used to enumerate several immune cell phenotypes. RESULTS: It was concluded that the invasion of B. canis contributes to the decreased percentage of CD3+, CD4+, CD8+, CD21+ lymphocytes in the blood of infected animals. The decreased level of tested subpopulations of lymphocytes in group 2 persisted for the entire 12-day period of the test. After the administration of imidocarb, each tested lymphocyte fraction in the blood of the dogs with babesiosis increased, but did not reach physiological values. CONCLUSION: The presented results indicate that the resolution of clinical signs associated with babesiosis may be related to the stimulation and intensity of cellular immunity, dependent on the CD4+ T cells profile. After administration of imidocarb, the parasitemia is cleared which allows the recovery of the lymphocyte populations.
Asunto(s)
Babesia/aislamiento & purificación , Babesiosis/tratamiento farmacológico , Babesiosis/inmunología , Enfermedades de los Perros/tratamiento farmacológico , Enfermedades de los Perros/inmunología , Imidocarbo/uso terapéutico , Subgrupos Linfocitarios/inmunología , Animales , Antiprotozoarios/uso terapéutico , Estudios de Casos y Controles , Perros , Femenino , Citometría de Flujo/veterinaria , Subgrupos Linfocitarios/patología , MasculinoRESUMEN
Lentiviral vectors have proven to be promising tools for transduction of brain cells in vivo and in vitro. In this study, we have examined the central nervous system (CNS) transduction efficiencies and patterns of a self-inactivating simian immunodeficiency virus (SIVmac)-derived lentiviral vector pseudotyped with glycoproteins from the vesicular stomatitis virus (VSV-G), the amphotropic murine leukemia virus (MLV4070Aenv), the lymphocytic choriomeningitis virus (LCMV-GP), the Ross River virus (RRV-GP) and the rabies virus (RV-G). All glycoproteins were efficiently incorporated into SIV virions, allowing efficient transduction of neuronal cell lines as well as of primary dissociated mouse brain cell cultures. After injection of highly concentrated vector stocks into the striatum of adult mice, quantitative analyses revealed high transduction efficiency with VSV-G pseudotypes, while LCMV-GP and RV-G pseudotypes exhibited moderate transduction efficiencies. MLV4070Aenv and RRV-GP pseudotypes, however, showed only weak levels of transduction after stereotactic injection into the brain. Regarding cell tropism in vivo, VSV-G-pseudotyped SIV vectors transduced neuronal as well as glial cells, whereas all other pseudotypes preferentially transduced neuroglial cells. In addition, we analyzed the influence of the central polypurine tract (cPPT) in context of the VSV-G-pseudotyped SIV transfer vector for infection of brain cells. Deletion of the cPPT sequence from the transfer vector decreased the in vivo transduction efficiency by fourfold, and, more importantly, this modification changed the transduction pattern, since these vectors were no longer able to infect neuronal cells in vivo. Vector injection into the brain did elicit a humoral immune response in the injected hemisphere; however, no gross signs of inflammation could be detected. Analysis of the biodistribution of the vector revealed that, besides the injected brain region, no vector-specific sequences could be detected in any of the organs evaluated. These data indicate SIV vectors as efficient gene delivery vehicles for the treatment of neurodegenerative diseases.
Asunto(s)
Encéfalo/metabolismo , Terapia Genética/métodos , Vectores Genéticos/genética , Virus de la Inmunodeficiencia de los Simios/genética , Transducción Genética/métodos , Animales , Anticuerpos Antivirales/sangre , Encéfalo/inmunología , Encefalopatías/terapia , Línea Celular , Línea Celular Tumoral , Células Cultivadas , Cuerpo Calloso/virología , Cuerpo Estriado/virología , Expresión Génica , Ingeniería Genética , Vectores Genéticos/inmunología , Vectores Genéticos/farmacocinética , Proteínas Fluorescentes Verdes/genética , Células HeLa , Humanos , Ratones , Ratones Endogámicos BALB C , Distribución TisularRESUMEN
BACKGROUND: A major prerequisite for the design of retroviral vectors encoding cell toxic or harmful genes is the possibility to tightly control gene expression, thus limiting activity to the relevant target cells and protecting the packaging cell used for production of recombinant viral particles. METHODS: In the present study a system was developed in which genetic reshuffling during the retroviral life cycle is exploited, allowing reconstitution of functional expression cassettes from separate elements exclusively in transduced target cells. For construction of these murine leukaemia virus (MLV)-based reconstituting viral vectors (ReCon), a promoterless inverted enhanced green fluorescent protein (EGFP) reporter gene cassette was inserted in place of the U3 region of the 3' LTR. Subsequently, the human ubiquitin promoter was inserted in the inverse orientation into the R/U5 border of the 5' LTR of the vector. RESULTS: PA317 packaging cells stably transfected with ReCon vectors were established and EGFP expression was analysed by fluorescence-activated cell sorting (FACS). After detection of low-level background expression, an additional polyadenylation signal was introduced in antisense orientation into the 3' LTR at the R/U5 border to prevent accidental read-through transcription from neighbouring cellular promoters. Virus-containing cell culture supernatants were then used to infect NIH3T3 target cells. EGFP expression, recloning and sequencing of integrated proviruses demonstrated the correct reassembly of the transduced ubiquitin/EGFP transcription unit in these infected cells. CONCLUSIONS: This facile and convenient system should allow production of retroviral vectors encoding potentially toxic proteins, cell cycle inhibitors or inducers of apoptosis, all of which would interfere with vector production if expressed in the retroviral packaging cell.
Asunto(s)
Vectores Genéticos , Retroviridae/genética , Células 3T3 , Animales , Cartilla de ADN/química , Citometría de Flujo , Regulación de la Expresión Génica , Proteínas Fluorescentes Verdes , Proteínas Luminiscentes/genética , Ratones , Reacción en Cadena de la Polimerasa , Regiones Promotoras Genéticas , Análisis de Secuencia de ADN , Secuencias Repetidas Terminales/genética , Transcripción Genética/genética , Transducción Genética , Transgenes/fisiologíaRESUMEN
Pancreatic carcinoma ranks as the eighth most frequent type of solid tumour arising worldwide yet it represents the fourth most frequent cause of death. This discrepancy reflects the current lack of effective treatment available for the pancreatic cancer patient and highlights the urgent need for new therapeutic principles in this area. The last five years have seen an increasing number of novel approaches both in the pre-clinical area as well as in clinical trials for pancreatic cancer treatments. This review summarizes these new developments and attempts to rationalize the possibilities available for the patient at the beginning of the new millennium.
Asunto(s)
Carcinoma/terapia , Neoplasias Pancreáticas/terapia , Adyuvantes Inmunológicos/farmacología , Adyuvantes Inmunológicos/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Antineoplásicos/uso terapéutico , Bilis , Biotransformación , Vacunas contra el Cáncer/uso terapéutico , Carcinoma/tratamiento farmacológico , Carcinoma/mortalidad , Ensayos Clínicos como Asunto , Citocromo P-450 CYP2B1/administración & dosificación , Citocromo P-450 CYP2B1/genética , Citosina/análogos & derivados , Citosina/uso terapéutico , ADN sin Sentido/uso terapéutico , Desoxicitidina/análogos & derivados , Desoxicitidina/uso terapéutico , Dioxolanos/uso terapéutico , Endopeptidasas/uso terapéutico , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/uso terapéutico , Genes p53 , Genes ras , Terapia Genética , Proteínas de Choque Térmico/inmunología , Humanos , Ifosfamida/farmacocinética , Estudios Multicéntricos como Asunto , Proteínas de Neoplasias/antagonistas & inhibidores , Células Madre Neoplásicas/trasplante , Neoplasias Pancreáticas/tratamiento farmacológico , Neoplasias Pancreáticas/mortalidad , Pectinas/uso terapéutico , Proyectos Piloto , Poliaminas/uso terapéutico , Estudios Prospectivos , Prótesis e Implantes , Sesquiterpenos/uso terapéutico , Compuestos de Espiro/uso terapéutico , Extractos de Tejidos , Inhibidores de Topoisomerasa I , GemcitabinaRESUMEN
Long-term benefits of coronary angioplasty remain limited by the treatment-induced renarrowing of arteries, termed restenosis. One of the mechanisms leading to restenosis is the proliferation of smooth muscle cells. Therefore, proliferating cells of the injured arterial wall, which can be selectively transduced by retroviruses, are potential targets for gene therapy strategies. A direct single-dose therapeutic application of retroviral vectors for inhibition of cell proliferation is normally limited by too low transduction efficiencies. Encapsulated retrovirus-producing cells release viral vectors from microcapsules, and may enhance the transduction efficiency by prolonged infection. Primary and immortal murine and porcine cells and murine retrovirus-producing cells were encapsulated in cellulose sulphate. Cell viability was monitored by analysing cell metabolism. Safety, stability, transfer efficiency and extent of restenosis using capsules were determined in a porcine restenosis model for local gene therapy using morphometry, histology, in situ beta-galactosidase assay and PCR. Encapsulation of cells did not impair cell viability. Capsules containing retrovirus-producing cells expressing the beta-galactosidase reporter gene were implanted into periarterial tissue or a pig model of restenosis. Three weeks following implantation, beta-galactosidase activity was detected in the pericapsular tissue with a transduction efficiency of approximately 1 in 500 cells. Adventitial implantation of vector-producing encapsulated cells for gene therapy may, therefore, facilitate successful targeting of proliferating vascular smooth muscle cells, and allow stable integration of therapeutic genes into surrounding cells. The encapsulation of vector-producing cells could represent a novel and feasible way to optimize local retroviral gene therapy.
Asunto(s)
Trasplante de Células/métodos , Celulosa/análogos & derivados , Composición de Medicamentos/métodos , Técnicas de Transferencia de Gen , Retroviridae/genética , Células 3T3 , Animales , Secuencia de Bases , División Celular , Células Cultivadas , Reestenosis Coronaria/patología , Reestenosis Coronaria/terapia , Cartilla de ADN/genética , Genes Reporteros , Vectores Genéticos , Ratones , Músculo Liso Vascular/patología , Porcinos , beta-Galactosidasa/genéticaRESUMEN
Feline kidney cells were transfected with a vector overexpressing cytochrome P450 2B1 (CYP2B1). Transfected cells acquired a new specific biochemical activity, which could be demonstrated by a rapid CYP2B1 detection assay and showed selective sensitivity to the antitumorigenic prodrug ifosfamide (IFO). Further, the cell-killing effect was also mediated on nonmodified cells like feline kidney cells, mouse lymphoma, and human pancreatic cells in the vicinity of the CYP2B1-expressing cells due to the diffusible nature of the activated IFO metabolites. One of these, phosphoramide mustard, causes interstrand DNA cross-linking and it has been thought that the inability to repair this damage results in apoptosis. Surprisingly, our results clearly demonstrate a necrotic mechanism of IFO-induced cell death. This may have important implications for the activation of the immune system during CYP2B1/IFO suicide gene therapy of cancer.
Asunto(s)
Antineoplásicos Alquilantes/uso terapéutico , Apoptosis , Citocromo P-450 CYP2B1/genética , Terapia Genética/métodos , Ifosfamida/uso terapéutico , Riñón/patología , Necrosis , Profármacos/uso terapéutico , Transfección/métodos , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/genética , Adenocarcinoma/patología , Animales , Gatos , Línea Celular , Células Cultivadas , Citocromo P-450 CYP2B1/metabolismo , Células Epiteliales/efectos de los fármacos , Células Epiteliales/ultraestructura , Citometría de Flujo , Vectores Genéticos , Humanos , Ifosfamida/metabolismo , Neoplasias Pancreáticas/tratamiento farmacológico , Neoplasias Pancreáticas/genética , Neoplasias Pancreáticas/patología , Profármacos/metabolismo , Sensibilidad y Especificidad , Células Tumorales CultivadasRESUMEN
Pancreatic cancer can seldom be resected, and chemotherapy has only a limited effect on survival or tumour load. We did a phase I/II trial in 14 patients with pancreatic cancer to assess the safety of local activation of low-dose ifosfamide. We encapsulated genetically modified allogeneic cells, which expressed a cytochrome P450 enzyme, in cellulose sulphate and delivered them by supraselective angiography to the tumour vasculature. These cells locally activated systemically administered ifosfamide. The tumours of four patients regressed after treatment, and those of the other ten individuals who completed the study remained stable. Median survival was doubled in the treatment group by comparison with historic controls, and 1-year survival rate was three times better. Further studies of this cell-therapy-based treatment combined with chemotherapy for inoperable pancreatic cancer are warranted.
Asunto(s)
Adenocarcinoma/terapia , Trasplante de Células/métodos , Citocromo P-450 CYP2B1/metabolismo , Ifosfamida/administración & dosificación , Cuidados Paliativos/métodos , Neoplasias Pancreáticas/terapia , Adenocarcinoma/diagnóstico , Adenocarcinoma/mortalidad , Adulto , Anciano , Anciano de 80 o más Años , Relación Dosis-Respuesta a Droga , Composición de Medicamentos , Sistemas de Liberación de Medicamentos/métodos , Femenino , Estudios de Seguimiento , Terapia Genética/métodos , Humanos , Masculino , Persona de Mediana Edad , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/mortalidad , Tasa de Supervivencia , Enfermo Terminal , Transfección , Trasplante Homólogo , Resultado del TratamientoRESUMEN
Determination of retroviral load is an important tool in the investigation of the success of therapeutic or vaccination trials in patients infected with lentiviruses such as HIV, or with their simian (SIV) or feline (FIV) counterparts. We have developed an one-tube quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) assay based on the ABI Prism 7700 Sequence Detection System (TaqMan) to quantify the viral load of FIV-infected cats. Two different primer/probe systems were designed to detect a broad range of clade A FIV isolates. Both systems are characterized by excellent reproducibility, high sensitivity, and a wide range of quantification. As a consequence of this improved precision in the quantitative RT-PCR, preassay variations have greater impact on the accuracy of the viral load estimation. To compensate for these variations, we improved the assay and developed a multiplex real-time RT-PCR, which allows simultaneous calculation of the viral copy number and the individual recovery rate in an one-tube reaction. This enables the rapid and accurate calculation of copy number independent of preassay variations. In further studies, two additional real-time RT-PCR assays were designed and used to investigate the influence of sequence variations in the binding regions for either the primers or probe. Sequence mismatches in this region had a significant effect (up to 4 logarithmic decades) on reaction efficiency. In view of the inherent variability of retroviral sequences, these results underline the necessity to check reaction efficiencies before determining viral load.
Asunto(s)
Disparidad de Par Base/genética , Virus de la Inmunodeficiencia Felina/genética , Virus de la Inmunodeficiencia Felina/aislamiento & purificación , Infecciones por Lentivirus/virología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Carga Viral , Animales , Secuencia de Bases , Gatos , Línea Celular , Cartilla de ADN/genética , Fluorescencia , Variación Genética/genética , Estándares de Referencia , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Moldes Genéticos , Factores de TiempoRESUMEN
We investigated whether CD4 gene regulatory sequences might be useful for developing transcriptionally targeted Moloney murine leukemia virus (Mo-MLV)-based retroviral vectors for gene expression specifically in CD4(+) cells. We could modulate Mo-MLV long terminal repeat (LTR) activity by inserting a 438-bp-long fragment containing the murine CD4 silencer in the LTR of the vector; both beta-galactosidase and green fluorescent protein reporter gene activities were strongly down-regulated in both murine and human CD8(+) cells, but not in CD4(+) lymphoid cell lines and freshly isolated lymphocytes transduced with this vector, compared with the findings using a control vector carrying wild-type LTRs. Titration experiments on NIH-3T3 cells revealed that inclusion of the CD4 silencer in the LTRs did not reduce the titer of the vectors. These findings indicate that a cellular silencer can be successfully included in retroviral vectors, where it maintains its transcription-regulatory function, thus suggesting a novel approach to transcriptional targeting.
Asunto(s)
Antígenos CD4/genética , Vectores Genéticos , Virus de la Leucemia Murina de Moloney/genética , Secuencias Repetidas Terminales , Transcripción Genética , Células 3T3 , Animales , Terapia Genética , Proteínas Fluorescentes Verdes , Humanos , Proteínas Luminiscentes/genética , Linfocitos/metabolismo , Ratones , Regiones Promotoras Genéticas , beta-Galactosidasa/metabolismoRESUMEN
Continuous and sustained in vivo production of monoclonal antibodies by engineered cells might render long-term antibody-based treatments cost-effective, avoid side effects associated with infusion of massive doses of antibody, and circumvent possible antiidiotypic responses against the therapeutic agent. The FrCasE retrovirus induces a lethal neurodegeneration on infection of newborn mice. We report here that implantation of cellulose sulfate capsules containing cells secreting an ectopic monoclonal antibody neutralizing FrCasE can prevent animals from developing the disease. All treated mice showed reduced or undetectable viremia in addition to a lack of the histopathological lesions characteristic of FrCasE infection. This work paves the way for a novel gene/cell antibody-based immunotherapy of a variety of severe viral and nonviral diseases.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Inmunoterapia/métodos , Retroviridae/inmunología , Viremia/terapia , Animales , Animales Recién Nacidos , Anticuerpos Monoclonales/metabolismo , Encéfalo/patología , Encéfalo/virología , Línea Celular , Virus de la Leucemia Murina de Friend/inmunología , Humanos , Ratones , Tiroglobulina/inmunología , Factores de Tiempo , Viremia/prevención & controlRESUMEN
The success of chemotherapeutic intervention is limited because the necessary high local drug doses cannot be achieved without systemic toxicity. Application of suicide genes (SGs) and direct conversion of prodrugs (PDs) to toxic metabolites in situ by SGs may enhance the efficacy of chemotherapy. To evaluate this strategy in two murine breast cancer models, TS/A and GR, we injected cellulose sulfate capsules harboring cat kidney cells expressing the SGs cytosine deaminase and cytochrome P450 2B1 (CYP2B1) intratumorally. The PDs 5-fluorocytosine and ifosfamide were administered in 3-day intervals. The effect of in situ chemotherapy with each PD alone and the combination was analyzed over a period of 100 days. The results reveal that for TS/A tumors, the antitumoral effect mediated by CYP2B1 is more efficient than that of cytosine deaminase, whereas for GR tumors, both systems worked equally well. Furthermore, we find additive toxicity using both SG/PD systems for both TS/A and GR tumors.
Asunto(s)
Citocromo P-450 CYP2B1/genética , Flucitosina/uso terapéutico , Terapia Genética/métodos , Ifosfamida/uso terapéutico , Neoplasias Mamarias Experimentales/tratamiento farmacológico , Nucleósido Desaminasas/genética , Profármacos/uso terapéutico , Animales , Gatos , Línea Celular , Trasplante de Células , Citocromo P-450 CYP2B1/metabolismo , Citosina Desaminasa , Femenino , Flucitosina/farmacocinética , Ifosfamida/farmacocinética , Riñón , Ratones , Ratones Endogámicos BALB C , Nucleósido Desaminasas/metabolismo , Profármacos/farmacocinética , Transfección , Células Tumorales CultivadasRESUMEN
Various forms of green fluorescent protein (GFP) have become important reporters of gene transfer and expression after transfection or infection of cells in cell culture. Frequently, molecular biological assays (Northern blots, PCR) are applied to detect reporter gene expression in target organs. However, these methods are not suitable for evaluation of tissue- or cell-specific expression which would be of great interest especially in case of using tissue-specific promoters. Therefore, organs of transgenic mice with the enhanced green fluorescent protein (EGFP) gene under control of the cytomegalovirus (CMV) promoter were processed for histology by formaldehyde fixation and embedding in paraffin. Sections were deparaffinized, mounted and evaluated for fluorescence in a confocal laser scanning microscope. This method combines the advantages of direct exploitation of tissue sections without further staining procedures with evaluable tissue-, cell-, and even subcellular-specific distribution patterns of EGFP expression in tissues. Results obtained by direct evaluation of EGFP fluorescence in paraffin sections were confirmed by immunohistochemical staining with anti-EGFP. In the present report, we demonstrate that application of confocal microscopy on routinely processed histological preparations is very suitable for determining gene transfer efficiency and promotor activities.
Asunto(s)
Indicadores y Reactivos/metabolismo , Proteínas Luminiscentes/metabolismo , Ratones Transgénicos/metabolismo , Microscopía Confocal/métodos , Animales , Expresión Génica , Proteínas Fluorescentes Verdes , Proteínas Luminiscentes/genética , Ratones , Ratones Endogámicos BALB C , Adhesión en Parafina , Regiones Promotoras Genéticas , Distribución TisularRESUMEN
Two major hurdles remain before xenotransplantation can enter the clinic. The first is the more technical issue of being able to overcome the human immune response that leads to rejection of transplanted organs/cells from other species. The second, reviewed here, concerns the potential risk of inadvertent transfer of animal viruses present in the xenotransplant that are able to infect the human recipient. The threat from viruses is a particularly contentious topic because it poses a risk not only to those individuals who receive xenotransplants, but also to healthy individuals who come into contact, either directly or indirectly, with the xenotransplant recipient. In this review, we describe some of the virus types, in addition to the much discussed porcine endogenous retroviruses that might cross the species barrier, and assess the risk of such viruses causing disease in human hosts.
Asunto(s)
Trasplante Heterólogo/efectos adversos , Virosis/transmisión , Zoonosis/transmisión , Animales , Infecciones por Herpesviridae/transmisión , Humanos , Retroviridae/inmunología , Retroviridae/patogenicidad , Infecciones por Retroviridae/transmisión , Medición de Riesgo , Especificidad de la Especie , Porcinos , Trasplante Homólogo , Virosis/inmunología , Virus/inmunología , Virus/patogenicidadRESUMEN
Transduction efficiency can be easily monitored during pre-clinical trials by inclusion of marker genes. However, the use of such marker genes should be avoided in the final clinical gene therapy application since their products are often immunogenic, making it difficult to monitor transduction, especially if the vector is applied in vivo. In these cases PCR-based methods like the real-time PCR might provide a powerful tool to estimate biodistribution. To investigate the accuracy of this method, we have developed and tested a real-time PCR assay for the quantification of the enhanced green fluorescent protein (EGFP) gene and compared the results with transduction efficiencies estimated by FACS analysis. Although our real-time PCR assay itself was characterized by a high precision over a wide dynamic range of quantification, significant differences in the transduction efficiency compared with FACS data were initially observed. Accurate determination could only be achieved using an optimized multiplex real-time PCR assay, which allows the simultaneous calculation of cell number and EGFP copy number in the same tube. In view of future needs for methods allowing precise and accurate analysis of biodistribution in gene therapy trials, our data highlight the necessity critically to check both parameters in the implemented assay.
Asunto(s)
Técnicas de Transferencia de Gen , Terapia Genética/métodos , Células 3T3 , Animales , Sistemas de Computación , Citometría de Flujo , Expresión Génica , Proteínas Fluorescentes Verdes , Humanos , Proteínas Luminiscentes/genética , Ratones , Reacción en Cadena de la Polimerasa/métodos , Sensibilidad y EspecificidadRESUMEN
In addition to the usual retroviral promoter, the mouse mammary tumor virus (MMTV) long terminal repeat carries a second promoter located in the U3 region. Here we show that both of these promoters are independently able to give rise to superantigen activity in transgenic mice. The ability of multiple MMTV promoters to drive superantigen expression underscores its importance in the virus life cycle.
Asunto(s)
Antígenos Virales/genética , Regulación Viral de la Expresión Génica , Virus del Tumor Mamario del Ratón/genética , Regiones Promotoras Genéticas , Superantígenos/genética , Secuencias Repetidas Terminales , Animales , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Superantígenos/biosíntesisRESUMEN
Murine cell-derived MLV vector particles usually are highly sensitive to human complement-mediated lysis. Expression of the human complement inhibitor CD59 on murine packaging cells resulted in partial protection of these cells from lysis caused by human complement proteins. Furthermore, CD59 was incorporated into MLV vector particles released by these packaging cells, leading to an improved resistance of the virions against human complement-mediated inactivation.
Asunto(s)
Antígenos CD59/inmunología , Proteínas Inactivadoras de Complemento/inmunología , Proteínas del Sistema Complemento/inmunología , Vectores Genéticos/genética , Virus de la Leucemia Murina/inmunología , Animales , Antígenos CD59/genética , Células Cultivadas , Proteínas Inactivadoras de Complemento/genética , Proteínas del Sistema Complemento/metabolismo , Humanos , Virus de la Leucemia Murina/genética , Ratones , TransfecciónRESUMEN
Percutaneous transluminal coronary angioplasty is a routinely used non-surgical revascularization technique for patients with coronary artery disease. Up to 30% of patients undergoing coronary angioplasty develop a renarrowing of treated vessels, called restenosis. Smooth muscle cell proliferation is thought to be an important factor in restenosis; this leads to neointima formation and arterial lumen narrowing. Neointima may be reduced by the transfer of genes encoding proteins with antiproliferative effects. Cecropins are antimicrobial peptides with antiproliferative properties in mammalian cells. Cecropin A is one member of this family of peptides. In this article, a plasmid carrying the gene for the immature form, pre-pro-cecropin A, complexed with liposomes was locally delivered to perivascular tissue in a porcine arterial injury model using a needle injection catheter. Retention of the plasmid in the treated arteries was demonstrated at both 8 and 21 days following application. Transferred plasmid DNA was not detected in any other tissues analyzed. Pre-pro-cecropin A-specific transcripts could also be found in treated arteries. Balloon-injured vessels demonstrated significantly reduced neointima at 21 days in vessels treated with the pre-pro-cecropin A gene compared with neointimal area in those given a control gene (P < 0.05). The needle injection catheter appears to be useful for local intravascular gene delivery. In vivo gene transfer of cecropins may be of therapeutic relevance in restenosis prevention by limiting cell proliferation.
Asunto(s)
Antiinfecciosos/metabolismo , Péptidos Catiónicos Antimicrobianos , Enfermedad Coronaria/terapia , Terapia Genética/métodos , Péptidos/genética , Angioplastia Coronaria con Balón , Animales , División Celular/genética , Terapia Genética/instrumentación , Vectores Genéticos/administración & dosificación , Vectores Genéticos/genética , Inmunohistoquímica , Inyecciones , Músculo Liso Vascular/patología , Profármacos/metabolismo , Recurrencia , PorcinosRESUMEN
Microencapsulation, as a tool for immunoisolation for allogenic or xenogenic implants, is a rapidly growing field. However most of the approaches are based on alginate/polylysine capsules, despite this system's obvious disadvantages such as its pyrogenicity. Here we report a different encapsulation system based on sodium cellulose sulfate and polydiallyldimethyl ammonium chloride for the encapsulation of mammalian cells. We have characterized this system regarding capsule formation, strength and size of the capsules as well as viability of the cells after encapsulation. In addition, we demonstrate the efficacy of these capsules as a "microfactory" in vitro and in vivo. Using encapsulated hybridoma cells we were able to demonstrate long-term release of antibodies up to four months in vivo. In another application we could show the therapeutic relevance of encapsulated genetically modified cells as an in vivo activation center for cytostatic drugs during tumor therapy.
Asunto(s)
Alginatos/química , Cápsulas/química , Polilisina/química , Animales , Anticuerpos Monoclonales/administración & dosificación , Línea Celular , Celulosa/análogos & derivados , Celulosa/química , Celulosa/toxicidad , Femenino , Ácido Glucurónico , Ácidos Hexurónicos , Humanos , Hibridomas , Masculino , Ratones , Ratones Desnudos , Estructura MolecularRESUMEN
We have previously demonstrated the therapeutic effect and efficacy of implantation of cells genetically modified to express cytochrome P450 2B1 in a nude mouse tumor model. The cells are encapsulated in polymerized cellulose sulphate and injected into preformed tumors. Upon administration of ifosfamide, the P450 enzyme converts the ifosfamide into antitumorigenic toxic metabolites at the site required, thereby significantly reducing tumor burden. Feline kidney epithelial cells were chosen for these studies, because they are easy to culture and can readily be transfected. However, these cells are not suitable for eventual use in human patients, since they are known to express endogenous retroviruses that are able to infect mammalian cells. They thus represent a safety risk. Here we describe the establishment of a human cell line that has been genetically modified to express the same cytochrome P450 construct and their characterization. The usefulness of mitomycin C treatment, both to protect the cells from the toxic metabolites that they produce and to incapacitate these cells from replicating, should they escape from the capsules, has also been investigated.
Asunto(s)
Células Clonales/trasplante , Citocromo P-450 CYP2B1/genética , Terapia Genética , División Celular , Línea Celular , Relación Dosis-Respuesta a Droga , Expresión Génica , Técnicas de Transferencia de Gen , Humanos , Ifosfamida/farmacología , Mitomicina/farmacología , SeguridadRESUMEN
The prognosis of pancreatic cancer is poor, and current medical treatment is mostly ineffective. The aim of this study was to design a new treatment modality in an animal model system. We describe here a novel treatment strategy employing a mouse model system for pancreatic carcinoma. Embryonal kidney epithelial cells were genetically modified to express the cytochrome P450 subenzyme 2B1 under the control of a cytomegalovirus (CMV) immediate early promoter. This CYP2B1 gene converts ifosfamide to its active cytotoxic compounds, phosphoramide mustard, which alkylates DNA, and acrolein, which alkylates proteins. The cells were then encapsulated in a cellulose sulphate formulation and implanted into preestablished tumors derived from a human pancreatic tumor cell line. Intraperitoneal administration of low-dose ifosfamide to tumor bearing mice that received the encapsulated cells results in partial or even complete tumor ablation. Such an in situ chemotherapy strategy utilizing genetically modified cells in an immunoprotected environment may prove useful for solid tumor therapy in man.